Inovio Pharma Stock
Inovio Pharma Stock
Our community is currently high on Inovio Pharma with 4 Buy predictions and 2 Sell predictions.
With a target price of 7 € there is potential for a 1215.79% increase which would mean more than doubling the current price of 0.53 € for Inovio Pharma.
Our community identified positive and negative aspects for Inovio Pharma stock for the coming years. 1 users see the criterium "Business model" as a plus for the Inovio Pharma stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Inovio Pharma in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Inovio Pharma vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Inovio Pharma | - | - | - | - | - | - | - |
| Heron Therapeutics Inc. | 0.680% | -14.277% | -26.750% | -66.583% | -34.246% | -66.275% | -94.415% |
| Evolus Inc | -0.470% | -7.792% | 16.393% | -64.202% | -21.835% | -46.750% | -60.592% |
| Sangamo Therapeutics Inc. | -5.120% | -7.955% | 4.651% | -58.679% | -7.376% | -82.989% | -96.755% |
Comments
Inovio Pharmaceuticals (NASDAQ:INO) had its "overweight" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for INO provided by MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Show more
Ratings data for INO provided by MarketBeat
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $5.00 price target on the stock.
Show more
Ratings data for INO provided by MarketBeat